Search

Your search keyword '"Rebecca Hickman"' showing total 4 results
Start Over Author "Rebecca Hickman" Topic business
4 results on '"Rebecca Hickman"'

1. Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010–2011 to 2017–2018

Author

Catharine Chambers, Danuta M. Skowronski, Yan Li, Jonathan B. Gubbay, Suzana Sabaiduc, Christine Martineau, Gaston De Serres, Hugues Charest, Tracy Chan, Anne-Luise Winter, Steven J. Drews, Kevin Fonseca, Mel Krajden, James A. Dickinson, Caren Rose, Martin Petric, Agatha N. Jassem, Rebecca Hickman, and Nathalie Bastien

Subjects
Adult, Male, 0301 basic medicine, Microbiology (medical), Trivalent influenza vaccine, Canada, cross-protection, Lineage (genetic), Adolescent, Databases, Factual, Cross Protection, 030106 microbiology, Young Adult, 03 medical and health sciences, Immunogenicity, Vaccine, 0302 clinical medicine, Vaccine strain, influenza vaccine effectiveness, Influenza, Human, Humans, Medicine, 030212 general & internal medicine, Child, Vaccine Potency, Aged, Influenza B viruses, business.industry, Influenzavirus B, repeat vaccination, Infant, Middle Aged, influenza B virus, Virology, 3. Good health, Vaccination, Infectious Diseases, Immunization, Influenza Vaccines, Child, Preschool, Epidemiological Monitoring, Female, Brief Reports, Seasons, business, lineage
Abstract

Vaccine effectiveness (VE) against influenza B was derived separately for Victoria and Yamagata lineages across 8 seasons (2010–2011 to 2017–2018) in Canada when trivalent influenza vaccine was predominantly used. VE was ≥50% regardless of lineage match to circulating viruses, except when the vaccine strain was unchanged from the prior season.

Published
2018

2. Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada

Author

Steven J. Drews, Suzana Sabaiduc, Gaston De Serres, Macy Zou, Yan Li, Rebecca Hickman, Mel Krajden, Tracy Chan, Catharine Chambers, Romy Olsha, Agatha N. Jassem, Danuta M. Skowronski, Nathalie Bastien, Siobhan Leir, Caren Rose, James A. Dickinson, Hugues Charest, Anne-Luise Winter, and Jonathan B. Gubbay

Subjects
Canada, Influenza vaccine, Hemagglutinin (influenza), Vaccine Efficacy, Disease cluster, Antigen, Influenza, Human, Immunology and Allergy, Medicine, Humans, Clade, Epidemics, Phylogeny, Phylogenetic tree, biology, business.industry, Influenza A Virus, H3N2 Subtype, Vaccination, Influenza a, Virology, Infectious Diseases, Influenza Vaccines, biology.protein, Seasons, business
Abstract

Background The influenza A(H3N2) vaccine was updated from clade 3C.3a in 2015–2016 to 3C.2a for 2016–2017 and 2017–2018. Circulating 3C.2a viruses showed considerable hemagglutinin glycoprotein diversification and the egg-adapted vaccine also bore mutations. Methods Vaccine effectiveness (VE) in 2016–2017 and 2017–2018 was assessed by test-negative design, explored by A(H3N2) phylogenetic subcluster and prior season’s vaccination history. Results In 2016–2017, A(H3N2) VE was 36% (95% confidence interval [CI], 18%–50%), comparable with (43%; 95% CI, 24%–58%) or without (33%; 95% CI, −21% to 62%) prior season’s vaccination. In 2017–2018, VE was 14% (95% CI, −8% to 31%), lower with (9%; 95% CI, −18% to 30%) versus without (45%; 95% CI, −7% to 71%) prior season’s vaccination. In 2016–2017, VE against predominant clade 3C.2a1 viruses was 33% (95% CI, 11%–50%): 18% (95% CI, −40% to 52%) for 3C.2a1a defined by a pivotal T135K loss of glycosylation; 60% (95% CI, 19%–81%) for 3C.2a1b (without T135K); and 31% (95% CI, 2%–51%) for other 3C.2a1 variants (with/without T135K). VE against 3C.2a2 viruses was 45% (95% CI, 2%–70%) in 2016–2017 but 15% (95% CI, −7% to 33%) in 2017–2018 when 3C.2a2 predominated. VE against 3C.2a1b in 2017–2018 was 37% (95% CI, −57% to 75%), lower at 12% (95% CI, −129% to 67%) for a new 3C.2a1b subcluster (n = 28) also bearing T135K. Conclusions Exploring VE by phylogenetic subcluster and prior vaccination history reveals informative heterogeneity. Pivotal mutations affecting glycosylation sites, and repeat vaccination using unchanged antigen, may reduce VE.

Published
2019

3. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018

Author

Nathalie Bastien, Mel Krajden, Yan Li, Jonathan B. Gubbay, James A. Dickinson, Steven J. Drews, Catharine Chambers, Danuta M. Skowronski, Rebecca Hickman, Gaston De Serres, Hugues Charest, Anne-Luise Winter, Agatha N. Jassem, and Tracy Chan

Subjects
0301 basic medicine, medicine.medical_specialty, Epidemiology, influenza virus, 03 medical and health sciences, 0302 clinical medicine, Antigen, Virology, Interim, genomics, medicine, 030212 general & internal medicine, vaccine effectiveness, business.industry, Public Health, Environmental and Occupational Health, virus diseases, Influenza a, mid-season, Influenza, Confidence interval, Vaccination, vaccine-preventable diseases, vaccines and immunisation, 030104 developmental biology, Immunization, Vaccine-preventable diseases, business, Rapid Communication
Abstract

Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): −14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results